3,3′-Diindolylmethane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells

Journal of Nutrition

Volumn 138, Issue 12, 2008, Pages 2379-2385

  Smith, Sunyata ^a,b   Sepkovic, Daniel ^c   Bradlow, H Leon ^c   Auborn, Karen J ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c David and Alice Institute for Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 3 INDOLEMETHANOL; 3,3' DIINDOLYLMETHANE; ANDROGEN RECEPTOR; BICALUTAMIDE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1A1; ESTROGEN; GENISTEIN; LUCIFERASE; PROSTATE SPECIFIC ANTIGEN; 3,3'-DIINDOLYLMETHANE; ANTINEOPLASTIC AGENT; ESTRADIOL; INDOLE DERIVATIVE; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ESTROGEN METABOLISM; GENE EXPRESSION; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; DIET; GENETICS; MALE; METABOLISM; NUCLEOTIDE SEQUENCE; PROSTATE TUMOR; RISK FACTOR; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; BASE SEQUENCE; CATECHOL O-METHYLTRANSFERASE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROME P-450 CYP1A1; DIET; ESTRADIOL; GENE EXPRESSION; GENISTEIN; HUMANS; INDOLES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RISK FACTORS; RNA, MESSENGER;

EID: 57349101528     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.108.090993     Document Type: Article

References (60)

1. Ho SM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem. 2004;91:491-503.
2. Ellem SJ, Risbridger GP. Treating prostate cancer: a rational for targeting local oestrogens. Nat Rev Cancer. 2007;7:621-7.
3. Risbridger GP. Androgens vs estrogens in prostate cancer. Endrocrine Abstracts. 2003;5:S7.
4. Griffiths K. Estrogens and prostatic disease. Prostate. 2000;45:87-100.
5. Steiner MS, Raghow S, Neubauer B. Selective estrogen receptor modulators for the chemoprevention of prostate cancer. Urology. 2001;57:68-72.
6. Krieg M, Nass R, Tunn SS. Effect of aging on endogenous level of 5α-dihydrotestoterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab. 1993;77:375-81.
7. Rohrmann S, Nelson WG, Rifai N, Brown TR, Dobs A, Kanarek N, Yager JD, Platz EA. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab. 2007;92:2519-25.
8. Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr. 2000;27:39-66.
9. Arnold JT, Le H, McFann KK, Blackman MR. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab. 2005;288:E573-84.
10. Wang Y, Hayward SW, Donjacour AA, Young P, Jacks T, Sage J, Dahiya R, Cardill RD, Day ML, et al. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res. 2000;60:6008-17.
11. Walsh PC, Wilson JD. The induction of prostatic hypertrophy in dog with androstanediol. J Clin Invest. 1976;57:1093-7.
12. Lord RS. Estrogen metabolism and the diet-cancer connection: rational for assessing the ratio of urinary hydroxylated estrogen metabolites-estrogen metabolism/cancer review. Altern Med Rev. 2002;7:112-29.
13. Nagata Y, Sonoda T, Mori M, Miyanaga N, Okumura K, Goto K, Naito S, Fujimoto K, Hirao Y, et al. Dietary isoflavones may protect against prostate cancer in Japanese men. J Nutr. 2007;137:1974-9.
14. Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev. 2003;12:665-8.
15. Kirsh VA, Peters U, Mayne ST, Subar AF, Chatterjee N, Johnson CC, Hayes RB. Prostate, lung, colorectal and ovarian cancer screening trail. Prospective study of fruit and vegetables intake and risk of prostate cancer. J Natl Cancer Inst. 2007;99:1200-9.
16. Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst. 2000;92:61-8.
17. Onozawa M, Fukuda K, Ohtani M, Akaza H, Sugimura T, Wakabayashi K. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cell line LNCaP. Jpn J Clin Oncol. 1998;28:360-3.
18. Santibanez JF, Navarro A, Martinez J. Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines. Anticancer Res. 1997;17:1199-204.
19. Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate. 2001;46:98-107.
20. Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein suppress chemically-induced prostate cancer in Lound-Wistar Rats. Cancer Lett. 2002;186:11-8.
21. Mentor-Marcel R, Lamartiniere CA, Greenberg NM, Elagavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res. 2001;61:6777-82.
22. Kumar NB, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R, Pow-Sang J. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004;59:141-7.
23. Brignall MS. Prevention and treatment of cancer with indole-3-carbinol. Altern Med Rev. 2001;6:580-9.
24. Nachshon-Kedmi M, Yannai S, Haj A, Fares FA. Indole-3-carbinol and 3′3-diindolylmethane induce apoptosis in human prostate cancer-cells. Food Chem Toxicol. 2003;41:745-52.
25. Nachshon-Kedmi M, Fares F, Yannai S. Therapeutic activity of 3′3-diindolylmethane on prostate cancer in an in vivo model. Prostate. 2004;61:153-60.
26. Auborn KJ, Fan S, Rosen EM, Goodwin L, Chandraskaren A, Williams DE, Chen D, Carter TH. Indole-3-carbinol is a negative regulator of estrogen. J Nutr. 2003;133:S2470-5.
27. Xu X, Duncan AM, Wangen KE, Kurzer MS. Soy consumption alters endogenous estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2000;9:781-6.
28. Bradlow HL, Sepkovic DW, Telang NT, Osborn MP. Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent. Ann N Y Acad Sci. 1999;889:204-13.
29. Dehennin L, Reiffsteck A, Scholler R. Simple methods for the synthesis of twenty different highly enriched deuterium labeled steroids suitable as internal standards for isotope dilution mass spectrometry. Biol Mass Spectrom. 1980;7:493-9.
30. Sepkovic DW, Bradlow HL, Michnovicz J, Murtezani S, Levy I, Osborne MP. Catechol estrogen production in rat microsomes after treatment with indole-3-carbinol, ascorbigen, or B-napthaflavone: a comparison of stable isotope dilution gas chromatography-mass spectrometry and radiometric methods. Steroids. 1994;59:318-23.
31. Raju U, Sepkovic DW, Dixon JM, Bradlow HL, Levitz M. Estrone and estradiol metabolism in vivo in human breast cysts. Steroids. 2000;65:883-8.
32. Jellinck PH, Makin HLJ, Sepkovic DW, Bradlow HL. Influence of indole carbinols and growth hormone on the metabolism of 4-androstenedione by rat liver microsomes. J Steroid Biochem Mol Biol. 1993;46:791-8.
33. Adlercreutz H, Martin F, Wahlroos O, Soini E. Mass spectrometric and mass fragmentographic determination of natural and synthetic steroids in biological fluids. J Steroid Biochem. 1975;6:247-59.
34. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GC, Jenster G, Trapman J, Brinkmann AO, Mulder E. The androgen receptor in LNCaP cells contains mutation in the ligand binding domain which effect steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol. 1992;41:665-9.
35. McDonald S, Brive L, Agus DB, Scher HI, Ely KR. Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res. 2000;60:2317-22.
36. Han M, Gann PH, Catalona WJ. Prostate-specific antigen and screening for prostrate cancer. Med Clin North Am. 2004;88:245-65.
37. Bu S, Blaukat A, Fu X, Heldin NE, Landstrom M. Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett. 2002;531:141-51.
38. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 1998;58:3833-8.
39. Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE. Androgen receptor and invasion in prostate cancer. Cancer Res. 2008;68:1128-35.
40. Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer. 2003;10:209-16.
41. Linja MJ, Savinainen KJ, Tammela TL, Isola JJ, Visakorpi T. Expression of ERalpha and ERbeta in prostate cancer. Prostate. 2003;55:180-6.
42. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res. 2000;60:3175-82.
43. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res. 2001;61:5331-5.
44. Yoshida T, Eguchi H, Nakachi K, Tanimoto K, Higashi Y, Suemasu K, Iino Y, Morishita Y, Hayashi S. Distinct mechanisms of loss of estrogen receptor alpha gene expression in human breast cancer: methylation of the gene and alteration of trans-acting factors. Carcinogenesis. 2000;21:2193-201.
45. Ji Q, Liu PI, Elshimali Y, Stolz A. Frequent loss of estrogen and progesterone receptors in human prostatic tumors determined by quantitative real-time PCR. Mol Cell Endocrinol. 2005;229:103-10.
46. Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, McInerney EM, William L. McGuire Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat. 1997;44:23-38.
47. Lykkesfeldt AE. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta Oncol. 1996;35:9-14.
48. Han G, Foster BA, Mistry S, Buchanan G, Harris JM, Tilley WD, Greenberg NM. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem. 2001;276:11204-13.
49. Le HT, Schaldach CM, Firestone GL, Bjeldanes LF. Plant-derived 3-3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem. 2003;278:21136-45.
50. Bektic J, Berger AP, Pfeil K, Dobler G, Bartsch G, Klocker H. Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor b. Eur Urol. 2004;45:245-51.
51. Castagnetta LA, Miceli MD, Sorci CMG, Pfeffer U, Farruggio R, Oliveri G, Calabro M, Carruba G. Growth of LNCaP human prostate cancer cells is stimulated by estradiol via it's own receptor. Endocrinology. 1995;136:2309-19.
52. Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korack KS. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. Cancer Res. 2001;61:6089-97.
53. Muti P, Westerlind K, Wu T, Grimaldi T, Berry J, Freudenheim JL, Hill H, Carruba G, Bradlow L. Urinary estrogen metabolites and prostate cancer: a case control study in the United States. Cancer Causes Control. 2002;13:947-55.
54. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 1998;19:1-27.
55. Brueggemeier RW, Gu X, Mobley JA, Joomprabutra S, Bhat AS, Whetstone JL. Effects of phytoestrogens and synthetic combinatorial libraries on aromatase, estrogen biosynthesis and metabolism. Ann N Y Acad Sci. 2001;948:51-66.
56. Bradlow HL, Telang NL, Sepkovic DW, Osborn MP. 2-Hydroxyestrone: the "good" estrogen. J Endocrinol. 1996;150:s259-65.
57. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA. 1998;85:7831-5.
58. Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL. Induction by estrogen metabolite 16α-hroxyestrone genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst. 1992;84:634-8.
59. Anderton MJ, Manson MM, Verschoyle RD, Gescher A, Lamb JH, Farmer PB, Steward WP, Williams ML. Pharmacokinetics and tissue disposition of indole-3-carbinol and it's acid condensation products after oral administration to mice. Clin Cancer Res. 2004;10:5233-41.
60. Rannikko A, Petas A, Rannikko S, Adlercreutz H. Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestrogen supplementation. Prostate. 2006;66:82-7.